SEC Tracker
Get the app
HBIO · XBRL financial data

Harvard Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (HBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers25,36328,153*24,51223,09721,96924,556*21,77420,45020,59123,735*20,75522,727
Cost of goods and services sold10,63611,828*9,7409,8799,20510,545*9,5908,9178,5709,563*8,51110,097
Gross profit14,72716,325*14,77213,21812,76514,011*12,18411,53312,02114,172*12,24412,630
Research and development2,7603,150*2,8852,6262,5672,328*2,3212,1892,1322,183*2,3262,453
General and administrative5,8075,286*5,9635,6865,0414,803*5,1854,2624,1764,119*4,7024,617
Total operating expenses15,66016,043*17,05115,28714,63914,000*61,85212,35211,82412,462*13,41813,608
Operating income (loss)(933)282*(2,279)(2,069)(1,874)11*(49,668)(819)1971,710*(1,174)(978)
Interest expense—————year only—800—year only—1,300
Other income (expense)45(332)*(142)(181)(518)189*(324)(644)(365)(1,323)*(405)(125)
Income tax expense (benefit)677715*210(353)311572*(454)2897(357)*11714
Net income (loss)(1,239)(1,818)*(4,694)(2,927)(4,802)18*(50,340)(2,282)(1,231)(2,847)*(3,424)(2,910)
Earnings per share, basic USD per share(0.03)(0.04)*(0.11)(0.07)(0.11)0.00*(1.14)(0.05)(0.03)(0.06)*(0.77)(0.64)
Earnings per share, diluted USD per share(0.03)(0.04)*(0.11)(0.07)(0.11)0.00*(1.14)(0.05)(0.03)(0.06)*(0.77)(0.64)
Weighted average shares, basic thousands of shares42,68842,512*43,40243,48643,61443,648*44,09644,30344,55644,602*4,4734,526
Weighted average shares, diluted thousands of shares42,68841,862*43,40243,48643,61443,648*44,09644,30344,55644,602*4,4734,526
  • † Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (HBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents5,3404,2834,2554,0484,5694,1085,5467,4426,8178,6147,0986,503
Accounts receivable14,98316,09915,30912,48612,83114,86613,47911,93712,10916,04314,57214,500
Inventory25,81824,71624,13625,13025,99023,24522,81622,25521,60420,80522,20522,230
Total current assets50,48649,03848,14846,43046,79145,11744,90244,96943,80548,22547,47946,463
Property and equipment, net3,3583,9814,4924,7585,2215,1065,0094,9134,9904,7874,8695,347
Right-of-use asset5,0614,7734,3594,4206,5236,1327,2837,1317,5007,1726,7306,400
Goodwill56,22257,06556,69956,62757,43956,3248,96010,1529,5259,5599,3729,330
Total assets139,735137,366133,161128,912131,239126,64479,80180,09377,99280,07177,93876,286
Accounts payable6,2695,5546,0445,7115,2834,7874,8084,7225,1763,6525,2876,224
Current portion of long-term debt3,7506,1394,0004,0004,00037,350———000
Total current liabilities24,20526,54225,67722,62122,75154,95855,60355,20254,39621,96023,86324,793
Long-term debt35,27330,70431,89031,96034,2520———35,87036,21136,682
Lease liability, non-current4,4184,7944,5574,7136,7066,3817,2306,9977,3326,8826,3595,926
Total liabilities65,44964,29264,34961,66565,91763,30464,96664,36063,92466,33767,89268,868
Accumulated deficit(143,787)(145,605)(150,299)(153,226)(158,028)(158,010)(208,350)(210,632)(211,863)(214,710)(218,134)(221,044)
Total stockholders' equity74,28673,07468,81267,24765,32263,34014,83515,73314,06813,73410,0467,418
Total liabilities and equity139,735137,366133,161128,912131,239126,64479,80180,09377,99280,07177,93876,286
Common shares outstanding (cover page) thousands of shares42,68843,39943,43043,61143,61744,07444,21444,53144,58044,7204,5104,552
  • † Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (HBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(1,239)(1,818)*(4,694)(2,927)(4,802)18*(50,340)(2,282)(1,231)(2,847)*(3,424)(2,910)
Stock-based compensation1,363*1,382*1,0481,278*1,053*961*600472*324*459*257380*
Net cash from operating activities4,361*4,303*1,403(846)*(842)*1,725*2,9862,755*1,084*(96)*(662)325*
Purchases of property and equipment217*830*645818*880*301*51389*207*449*426688*
Net cash from investing activities(401)*(1,061)*(225)458*(1,111)*(466)*(683)(233)*(348)*(599)*(620)(916)*
Proceeds from long-term debt—————year only———year only——
Repayments of long-term debt750*750*3,0231,000*1,000*1,000*1,0001,000*1,000*21,700*00*
Net cash from financing activities(2,750)*(4,116)*(1,055)177*2,104*(1,357)*(1,204)(1,258)*(1,278)*2,449*(9)(38)*
Net change in cash1,016*(1,057)*(28)(207)*521*(461)*1,4381,896*(625)*1,797*(1,516)(595)*
  • † Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Harvard Bioscience6,50322,727325*4.6M— 10-QJun 30, 2026
MultiSensor AI Holdings21,0051,695(2,392)*2.2M8.8 quarters 10-QJun 30, 2026
Precipio3,0757,021660*1.8M— 10-QJun 30, 2026
Focus Universal1,600675(741)*702,7452.2 quarters 10-QJun 30, 2026
Alamar Biosciences132,96929,427(11,322)*69.4M22.1 quarters 10-QJun 30, 2026
Optex Systems Holdings6,1759,7292,323*7.0M— 10-QJun 28, 2026
Data I/O10,8435,149(2,939)*10.4M3.7 quarters 10-QJun 30, 2026
Bionano Genomics3,7308,171(4,670)*11.8M2.1 quarters 10-QJun 30, 2026
ClearSign Technologies9,889not reported(1,236)*6.8M8.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.